Canadian senators call for immediate launch of massive psychedelic research program; plus updates from PharmAla and Clearmind.
Cybin Inc.'s new drug for treating depression meets major milestone. Plus a new study on DMT and a new effort from congress to protect state and local Government's ability to create their own psychedelic policies.
Did Cybin just take the top spot on the psychedelics food chain? Plus Beckley goes global and California goes back to the ballot box.
Wanna get ahead in corporate America? Consider LSD! And Alabama is famous for football, but could it soon be famous for psychedelics too?
California may create a government agency dedicated to psychedelic research (and they've already got a clever acronym for it)
California misses big opportunity, but still takes important step towards legalization. And could psychedelics treat obsessive behavior?
Cybin announces new agreement with Fluence. Congress considers including psychedelic research and therapy in Department of Defense funding.
Groundbreaking Enthea announcement makes ketamine-assisted therapy an employee benefit; could psychedelics treat postpartum depression?
MDMA cures PTSD in 72% of test subjects; Buckley Waves secures massive funding round; California lawmakers decriminalize mushrooms.
How the Wolf of Wall Street cured his opiate addiction with psychedelics; plus California and Massachusetts advance legalization measures.
Big pharma ponies up to get a piece of the psychedelics market; Cybin and Small Pharma merge; Filament signs major licensing deal.
Compass Pathways announces $285 million private placement; can co-use of MDMA and psilocybin/LSD lead to better trips?
Chronic pain and depression and neuroplasticity (Oh my!). New studies reveal the breadth and depth of psychedelics' therapeutic potential.
The surprising ways psilocybin use impacts how we work; Massachusetts activists seek to get a pair of initiatives on the 2024 ballot.
Minneapolis decriminalizes psychedelics. California pushes for legalization statewide and federally in 2024.
Psychedelics could save your relationship; California readies two ballot measures; how psychedelics treat or even cure eating disorders.
Bi-partisan lawmakers push to include funding for psychedelic research and treatment in sweeping defense bill; AMA reveals full CPT code.
Cambridge University publishes comprehensive evidence on the efficacy of psychedelics in treating depression; a new ibogaine documentary from Lucy Walker.
California and Australia advance psychedelic legalization; more research reveals the efficacy of psychedelics in treating eating disorders therapeutic goods administration
A shoe tycoon becomes the latest billionaire to invest in psychedelics; a new study shows how psychedelics can help people process grief.
Oprah talks psychedelics with an industry icon; Rhode Island House of Representatives overwhelmingly passes psilocybin mushroom reform.
How US military veterans are accelerating the push to legalize psychedelics; Algernon Pharmaceuticals crosses another milestone in its clinical study of formulation of AP-188.
Kentucky allocates opioid settlement money for psychedelics research; European Parliament paves way for psychedelic-assisted treatments.
In the race to see which state will fully legalize psychedelics first, Minnesota, Colorado and California are neck, neck... and neck!
Could psychedelics help treat ALS? Plus North Carolina creates a grant for psychedelic research and Clearmind Medicine to begin new study.
American university becomes the first to receive a license to grow psilocybin mushrooms; Arizona and Oregon move towards clinical treatment.
The American Medical Association makes a historic step toward allowing psychedelic treatment; and could psychedelics cure color blindness?
How psychedelics can significantly reduce depression in people with an advanced cancer diagnosis; Minnesota prepares for legalization.
Tonight on Sports Center... psychedelics? Plus psychedelic therapy becomes an official area of study at a prestigious UK university.
Hawaii is on the cusp of providing breakthrough psilocybin and MDMA therapies; psychedelics gain traction in Europe and Australia.
The new champion of psychedelics reform? The most conservative member of the Massachusetts legislature.
Grassroots efforts in Massachusetts lead to a record number of psychedelics bills; exploring the role of psychedelics in hospice care.
A new study reveals insights into how DMT affects the brain; Oregon becomes the first state to grant a production license for psilocybin.
Psychedelics show success in treating both fibromyalgia and Lyme disease. Texas lawmakers expand research into psychedelics.
Will congress reclassify psychedelics for research and treatment? And more studies demonstrate psychedelics' ability to treat depression.
Congress forms a bi-partisan caucus to promote research into and awareness of psychedelics; plus how psychedelics could help treat anorexia.
Could psychedelics help heal the Ukrainian people? Plus Awakn partners with a secret company in Portugal and Gilgamesh gives an update.
Algernon completes dosing the first cohort in its Phase 1 clinical study. Arizona moves forward a bill to research psilocybin mushrooms.
Awakn Life Sciences granted fast-track for ketamine-assisted therapy for Alcohol Use Disorder; Hawaii moves toward embracing psychedelics.
Revive Therapeutics and PharmaTher to develop an MDMA transdermal patch. More than a dozen states introduce psychedelic legislation.
Diamond Therapeutics begins a historic new study; the US Department of Veterans Affairs considers new guidelines to protect psilocybin use.
Algernon NeuroScience doses the first subjects in its DMT trial; Arizona and New Hampshire could be the next states to legalize psychedelics.
Could psychedelics repair consciousness after brain trauma? And lawmakers in nearly a dozen states are already pursuing psychedelics reform legislation in 2023
Could psychedelics cure binge eating and irritable bowel syndrome? Plus psychedelic legalization gains ground in Oregon and New York
Colorado announces certain psychedelics are now legal to possess and grow; Another study suggests a dose of psilocybin can ease depression.
Plus psychedelic treatment for veterans gains traction at the Rand Corporation and George W. Bush Institute.
Germany and Canada expand funding for psychedelic research; Diamond Theareuptics completes historic phase I study.
A new study assesses trends in psychedelics legislation, and an article wonders if employers might start covering psychedelic treatments.
Plus Berkley advances a proposal to decriminalize certain psychedelics, including LSD; and did Vikings really ingest psychedelics before battle?
Plus how to educate psychoanalysts about psychedelics, and how ibogaine can help people overcome addiction.
Plus MAPS completes a study of MDMA-assisted therapy for PTSD; members of congress take on historic psychedelic research initiatives.
Plus Colorado voters pass a ballot initiative to expand psychedelic legalization; Beckley Psytech begins Phase I clinical trial on ELE-101.
Plus Lusaris Therapeutics launches with a huge investment from RA Capital; Psilocybin continues to show promise in treating depression.
Buckey Psychtech's move is sure to shake up the psychedelics industry; John Hopkins University receives federal grant to study psychedelics as possible treatment for cigarettes.
Silo Pharma announces a new drug for treating dementia with ketamine as an active ingredient; new PBS documentary explores psychedelics; Cory Booker suggests federal government reclassify psychedelics.
Psychedelic therapy is emerging as an effective treatment for a variety of mental health concerns, such as major depressive disorder, postpartum depression and PTSD.
Fluence poised to become a leading trainer of psilocybin facilitators in Oregon and beyond. New York revises its bill to legalize psychedelics. Alberta brings psychedelic therapy to Canada.
New articles explore psychedelics as a potential secondary method for treating cancer, migraines and other conditions. And a new state looks to provide legal psychedelic therapy for veterans and frontline workers.
Biomind Labs completes dosing for Phase II trial of BMND01, and the mainstream media and boomers begin to embrace psychedelics.
Awakn Life Sciences to begin feasibility study for MDMA oral tablets; Algernon to begin study treating stroke victims with DMT; and does microdosing impact meditation?
San Francisco city council voted unanimously to decriminalize psychedelics; Georgia lawmakers talked next steps for psychedelics research for military veterans.
Cybin Inc. makes progress in phase 1/2a trial. Missouri considers psychedelics as solution to military veteran suicide crisis.
MindMed Inc. begins Phase 2 trial of MM-120 for treating anxiety; New study suggests psilocybin can help treat alcoholism; DEA withdraws proposal to ban certain hallucinogens after push back from researchers.
Cybin, Inc. receives Schedule I license to begin dosing patients in first-in-human study of CYB003. Thailand to make shroom-based medicine.
John Hopkins researcher believes psychedelics can improve memory, MIT publishes controversial study on psychedelics and VR, and Mindset Pharma CEO gives an update.
Green Bay Packers Quarterback Aaron Rodgers opens up about ayahuasca experiences. Plus Morgan Stanley is very optimistic about the future of psychedelics.
Biden administration to approve MDMA and psilocybin for designated therapies, San Francisco moves to decriminalize natural psychedelics.
Psychedelics bridge the political divide in the Senate and make the ballot in Colorado. And could psychedelics treat chronic pain?
Psilocybin trends, a psychedelic pioneer passes away, and PharmaTher Holdings to receive patent for ketamine treatment for motor disorders.
Awakn Life Sciences receives UK state funding for ketamine therapy program; study suggests microdosing psilocybin can improve mental health.
Colorado activists put psychedelic legalization on the ballot, Cybin receives FDA clearance for historic psilocybin clinical trial.
WSJ reports on how psychedelics are making their way into new stories and novels, and a new documentary from the BBC
Docu series from Michael Pollan explores the world of psychedelics, and study reveals one dose of psilocybin therapy can reduce depression.
Tryp Therapeutics announced the results of its first patient doses in its Clinical Trial for the treatment of binge eating disorder.
Maryland creates fund for psychedelic treatment for veterans with PTSD, new research promotes psilocybin therapy's mental health benefits.
Compass Pathways presents positive results on psilocybin therapy as depression treatment. Senator discusses positive effects of microdosing.Senator discusses positive effects of microdosing.
Canada approves Numinus Wellness application to complete psychedelic therapy to treat depression. JLS goes to World Economic Forum in Davos.
Connecticut budget funds psychedelic treatment. MindMed sees positive results from phase 2 trials evaluating LSD in anxiety disorders.
NIH explores the therapeutic potential of kratom. Colorado Governor supports decriminalizing psychedelics.
Tryp Therapeutics doses first patient in clinical trial for treating Binge Eating Disorder. Wesana takes the stage at Benzinga Conference.
Is VR effective for psychedelic-assisted psychotherapy? And which tech founder was featured in Forbes promoting his love of psychedelics?
Numinous will acquire Novamind, Cybin releases promising new data, and psychedelics make a prominent appearance in Harper’s Bazaar Magazine.
New study shows psilocybin may protect against opioid use disorder. Maryland and Colorado take steps toward expanding access.
The governor of Utah signs a bill to create a psychedelics task force. New study shows MDMA-assisted therapy is effective for treating PTSD.
Scientists use AI to map psychedelic experiences in the brain. And Awakn's flagship London ketamine clinic receives regulatory approval.
Good news for Psilocybin decriminalization in Oklahoma. And newly released research results for MDMA-assisted psychotherapy treating PTSD.
Which soap company just announced it will now offer psychedelic treatment to its workers as part of its healthcare benefits?
Another win this week for psilocybin mushrooms in Hawaii. And the DEA is facing challenges to its newest proposal to ban five tryptamines.
Big news out of the UK! M.A.P.S. landed an Innovation Passport for MDMA as an adjunct to therapy for PTSD.
Why did the Director of the National Institute on Drug Abuse say the “train has left the station” on psychedelics?
This week: a new study suggests ketamine may be an effective treatment to sustain abstinence from alcohol
Was the original Santa Clause an Arctic shaman? And a new setback for trials of LSD for the treatment of generalized anxiety disorder (GAD)
A New York lawmaker introduced a bill to legalize psilocybin for medical purposes, and three Canadians get permission to use psilocybin.
Research suggests microdosing reduces anxiety and depression, and the first formal test of the effect of psychedlics on metaphysical beliefs.
This week: psychedelic stocks took a nosedive on Tuesday, and Novamind secures insurance coverage for ketamine from four major providers.
Welcome to This Week in Psychedelics! Find out which US city just approved a ballot initiative to decriminalize psychedelics.
Activists press Oakland, CA to allow local producers to sell ethnogenic substances, UK Prime Minister Boris Johnson to consider reclassifying psilocybin
Pennsylvania, Denver and Detroit consider psilocybin decriminalization and/or therapy
New research indicates psychedelics can reduce opioid use by 55%. And microdosing is in the spotlight of a new study by MindMed.
Genentech's multiple sclerosis treatment shows major promise; atai Beckley to meet with the FDA about its new depression treatment.
.png){kind=small}
.jpeg)
